CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Antibe Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Antibe Therapeutics Inc
15 Prince Arthur Avenue
Phone: (905) 726-0995p:905 726-0995 TORONTO, ON  M5R 1B2  Canada Fax: (905) 570-5103f:905 570-5103
Placed under Receivership on 4/22/2024
On 4/9/2024, Antibe Therapeutics Inc. filed an application for Protection from its Creditors under the Companies' Creditors Arrangement Act (the "CCAA") with the Ontario Superior Court of Justice (Commercial List) (the "Court"). Deloitte Restructuring Inc. was appointed as the Monitor by the Court.
In addition, the Company announced that Amal Khouri and Jennifer McNealey have resigned from its Board of Directors effective 4/8/2024
On 4/22/2024, the CCAA proceedings for Antibe Therapeutics Inc were terminated and FTI Consulting Canada Inc. was appointed as the Receiver of the Company
This company is no longer actively traded on any major stock exchange.
Business Summary
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Robert E.Hoffman 58 5/25/2022 11/15/2020
President, Chief Executive Officer, Secretary, Director DanielLegault 8/30/2013 5/5/2009
Vice Chairman of the Board Walter M.Macnee 66 5/25/2022 2/26/2013
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 11 (As of 3/31/2023)
Outstanding Shares: 53,009,362 (As of 4/9/2024)
Stock Exchange: TSE
Fax Number: (905) 570-5103


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024